Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease

Trial Profile

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 28 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms AMARANTH
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 20 Jul 2023 Results of pooled analysis from NCT01900665, NCT02791191, NCT02245737, NCT02016560 assessing to understand the direct and indirect effects, mediated through amyloid levels, of the rs6733839 T-allele and APOE e4-allele on tau presented at the Alzheimer's Association International Conference 2023
    • 04 Aug 2022 Results (n=431) is to apply data-driven methods on regional tau measurements at baseline to identify a relatively homogeneous patient population showing earlier signals of tau from NCT02016560, NCT01900665, NCT02791191 and NCT02245737 studies, presented at the Alzheimer's Association International Conference 2022.
    • 31 Jul 2021 This trial has been completed in spain, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top